Table 1.
Characteristics of TennCare Study cohort, total and by race and sex
| Total Cohort | Black, Non-Hispanic | White, Non-Hispanic | P valueb | Female | Male | P valueb | |
|---|---|---|---|---|---|---|---|
|
|
|
||||||
| N=3,654 | N=1,948 | N=1,706 | N=1,070 | N=2,584 | |||
| Age at Entry Date in Years, Median (Range) | 36 (18–98) | 36 (18–87) | 36 (18–98) | 0.01 | 33 (18–87) | 37 (18–98) | <0.001 |
| Female Sex | 1,070 (29) | 776 (40) | 294 (17) | <0.001 | – | – | |
| Race | |||||||
| Non-Hispanic, black | 1,948 (53) | – | – | 776 (73) | 1,172 (45) | <0.001 | |
| Non-Hispanic, white | 1,706 (46) | – | – | 294 (27) | 1,412 (55) | ||
| Urban Residencea | 3,178 (87) | 1835 (94) | 1343 (79) | <0.001 | 944 (88) | 2,234 (87) | 0.16 |
| Enrollment Category | <0.001 | <0.001 | |||||
| Disabled | 1,976 (54) | 1,007 (52) | 969 (57) | 416 (39) | 1,560 (60) | ||
| Uninsured | 1,280 (35) | 637 (33) | 643 (38) | 333 (31) | 947 (37) | ||
| Aid to families of dependent children | 355 (10) | 284 (15) | 71 (4) | 317 (30) | 38 (1) | ||
| Qualified Medicare beneficiary | 37 (1) | 14 (<1) | 23 (1) | 2 (<1) | 35 (1) | ||
| Aged | 6 (<1) | 6 (<1) | – | 2 (<1) | 4 (<1) | ||
| Cohort qualifying Medication | |||||||
| Protease inhibitor | 2,757 (75) | 1,427 (73) | 1,330 (78) | 0.001 | 753 (70) | 2,004 (78) | <0.001 |
| Nelfinavir | 1,293 (47) | 800 (56) | 493 (37) | 430 (57) | 863 (43) | ||
| Indinavir | 1,105 (40) | 482 (34) | 623 (47) | 245 (33) | 860 (43) | ||
| Saquinavir | 155 (6) | 53 (4) | 102 (8) | 32 (4) | 123 (6) | ||
| Lopinavir/ritonavir | 142 (5) | 69 (5) | 73 (5) | 36 (5) | 106 (5) | ||
| Ritonavir | 39 (<1) | 12 (<1) | 27 (2) | 7 (<1) | 32 (2) | ||
| Amprenavir | 23 (<1) | 11 (<1) | 12 (<1) | 3 (<1) | 20 (1) | ||
| Non-nucleoside reverse transcriptase inhibitor | 897 (25) | 521 (27) | 376 (22) | 317 (30) | 580 (22) | ||
| Efavirenz | 407 (45) | 245 (47) | 162 (43) | 126 (40) | 281 (48) | ||
| Nevirapine | 490 (55) | 276 (53) | 214 (57) | 191 (60) | 299 (52) | ||
| Early HIV-Related Medical Encounters | 2,896 (79) | 1,469 (75) | 1,427 (84) | <0.001 | 825 (77) | 2,071 (80) | 0.04 |
| Early Drug Discontinuations | 1,153 (32) | 713 (37) | 440 (26) | <0.001 | 425 (40) | 728 (28) | <0.001 |
Data shown are n (%) except where noted otherwise.
a
Urban residence defined as primary residence in a county classified as a standard metropolitan statistical area;
b
P values for race and sex comparisons obtained from chi-squared, Fisher’s exact, and Wilcoxon rank-sum tests, as appropriate